

# Stephen P Glasser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2212858/publications.pdf>

Version: 2024-02-01

166  
papers

5,891  
citations

76294

40  
h-index

82499

72  
g-index

169  
all docs

169  
docs citations

169  
times ranked

7185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Hypertension, 2021, , .	1.0	6
2	C-reactive protein and risk of cognitive decline: The REGARDS study. PLoS ONE, 2020, 15, e0244612.	1.1	20
3	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
4	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
5	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
6	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
7	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
8	C-reactive protein and risk of cognitive decline: The REGARDS study. , 2020, 15, e0244612.		0
9	Serum Sodium and Pulse Pressure in SPRINT. American Journal of Hypertension, 2019, 32, 649-656.	1.0	5
10	Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial. Journal of Hypertension, 2018, 36, 904-915.	0.3	30
11	Long-Term Effects of an Intensive Lifestyle Intervention on Electrocardiographic Criteria for Left Ventricular Hypertrophy: The Look AHEAD Trial. American Journal of Hypertension, 2018, 31, 541-548.	1.0	7
12	N-terminal pro-B-type natriuretic peptide and microsize myocardial infarction risk in the reasons for geographic and racial differences in stroke study. BMC Cardiovascular Disorders, 2018, 18, 66.	0.7	5
13	Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004663.	0.9	18
14	Drugs don't work in patients who don't take them. Journal of Clinical Hypertension, 2018, 20, 1504-1506.	1.0	2
15	Serum Tumor Necrosis Factor-alpha associates with Myocardial Oxygen Demand and Exercise Tolerance in Postmenopausal Women. International Journal of Exercise Science, 2018, 11, 42-54.	0.5	1
16	Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiology, 2017, 2, 890.	3.0	95
17	Comparison of Expert Adjudicated Coronary Heart Disease and Cardiovascular Disease Mortality With the National Death Index: Results From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Journal of the American Heart Association, 2017, 6, .	1.6	51
18	The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). Journal of Clinical Hypertension, 2017, 19, 1152-1161.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Antihypertensive medications and sexual function in women. <i>Journal of Hypertension</i> , 2016, 34, 1224-1231.	0.3	31
20	Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 578-586.e5.	2.3	13
21	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 847-856.	2.3	56
22	Prevalence of electrocardiographic abnormalities based on hypertension severity and blood pressure levels: the Reasons for Geographic and Racial Differences in Stroke study. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 702-713.e4.	2.3	2
23	What is the association of lipid levels and incident stroke?. <i>International Journal of Cardiology</i> , 2016, 220, 890-894.	0.8	43
24	Gender, race, age, and regional differences in the association of pulse pressure with atrial fibrillation: the Reasons for Geographic and Racial Differences in Stroke study. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 625-632.e1.	2.3	1
25	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	3.1	19
26	Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Annals of Pharmacotherapy</i> , 2016, 50, 253-261.	0.9	25
27	Systolic blood pressure response after high-intensity interval exercise is independently related to decreased small arterial elasticity in normotensive African American women. <i>Applied Physiology, Nutrition and Metabolism</i> , 2016, 41, 484-490.	0.9	4
28	Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 323-331.	1.3	20
29	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	3.1	60
30	Stroke and Hypertension in High-Risk African Americans. , 2015, , 71-93.		0
31	Effects of Coenzyme Q10 on Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 24-34.	1.4	168
32	Should Acetaminophen Be Added to the List of Anti-Inflammatory Agents That Are Associated With Cardiovascular Events?. <i>Hypertension</i> , 2015, 65, 991-992.	1.3	5
33	Statin therapy and plasma coenzyme Q10 concentrationsâ€”A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	3.1	145
34	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.4	47
35	Raceâ€”Sex Differences in the Management of Hyperlipidemia. <i>American Journal of Preventive Medicine</i> , 2015, 48, 520-527.	1.6	29
36	Correlates of Incident Cognitive Impairment in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Clinical Neuropsychologist</i> , 2015, 29, 466-486.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First Century: Findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Current Hypertension Reports</i> , 2015, 17, 541.	1.5	21
38	Is Pulse Pressure an Independent Risk Factor for Incident Stroke, REasons for Geographic And Racial Differences in Stroke. <i>American Journal of Hypertension</i> , 2015, 28, 987-994.	1.0	25
39	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1864-1872.	1.2	24
40	Perceived Stress and Atrial Fibrillation: The REasons for Geographic and Racial Differences in Stroke Study. <i>Annals of Behavioral Medicine</i> , 2015, 49, 802-808.	1.7	23
41	Left Ventricular Hypertrophy and Incidence of Acute Coronary Heart Disease and Mortality in the Reasons for Geographic and Racial Differences in Stroke Study (REGARDS). <i>Cardiology and Angiology</i> , 2015, 3, 27-39.	0.0	1
42	Arterial Elasticity, Strength, Fatigue, and Endurance in Older Women. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	5
43	Is Pulse Pressure an Independent Risk Factor for Incident Acute Coronary Heart Disease Events? The REGARDS Study. <i>American Journal of Hypertension</i> , 2014, 27, 555-563.	1.0	49
44	Hemodynamic and Echocardiographic Profiles in African American Compared With White Offspring of Hypertensive Parents: The HyperGEN Study. <i>American Journal of Hypertension</i> , 2014, 27, 21-26.	1.0	7
45	Prehypertension and Incident Acute Coronary Heart Disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Hypertension</i> , 2014, 27, 245-251.	1.0	8
46	Statin Underuse and Low Prevalence of LDL-C Control Among U.S. Adults at High Risk of Coronary Heart Disease. <i>American Journal of the Medical Sciences</i> , 2014, 348, 108-114.	0.4	41
47	Cognitive Effects of Statin Medications. <i>CNS Drugs</i> , 2014, 28, 411-419.	2.7	40
48	Objective sleep, a novel risk factor for alterations in kidney function: the CARDIA study. <i>Sleep Medicine</i> , 2014, 15, 1140-1146.	0.8	41
49	Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease. <i>International Journal of Cardiology</i> , 2014, 174, 436-439.	0.8	9
50	Achievement of Optimal Medical Therapy Goals for U.S. Adults With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1626-1633.	1.2	31
51	Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. <i>Annals of Epidemiology</i> , 2014, 24, 581-587.	0.9	32
52	The Role of the USA Food and Drug Administration in Clinical Research. , 2014, , 117-143.		0
53	Phase 4 (Postmarketing) Research. , 2014, , 91-116.		0
54	The Placebo and Nocebo Effect. , 2014, , 145-176.		0

#	ARTICLE	IF	CITATIONS
55	A Focus on Clinical Trials. , 2014, , 33-74.		0
56	Assessment tools for unrecognized myocardial infarction: a cross-sectional analysis of the REasons for geographic and racial differences in stroke population. BMC Cardiovascular Disorders, 2013, 13, 23.	0.7	5
57	Hospital laboratory reporting may be a barrier to detection of â€microsizeâ€™™ myocardial infarction in the US: an observational study. BMC Health Services Research, 2013, 13, 162.	0.9	26
58	Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among U.S. Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes. Diabetes Care, 2013, 36, 2734-2740.	4.3	13
59	Primary Prophylactic Aspirin Use and Incident Stroke: Reasons for Geographic and Racial Differences in Stroke Study. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 500-507.	0.7	2
60	Changes in Vascular Hemodynamics in Older Women Following 16 Weeks of Combined Aerobic and Resistance Training. Journal of Clinical Hypertension, 2013, 15, 241-246.	1.0	20
61	Racial Differences in the Impact of Elevated Systolic Blood Pressure on Stroke Risk. JAMA Internal Medicine, 2013, 173, 46.	2.6	194
62	Trends in the Prevalence, Awareness, Treatment and Control of High Low Density Lipoprotein-Cholesterol Among United States Adults From 1999â€™2000 Through 2009â€™2010. American Journal of Cardiology, 2013, 112, 664-670.	0.7	58
63	Four-Year Change in Cardiorespiratory Fitness and Influence on Glycemic Control in Adults With Type 2 Diabetes in a Randomized Trial. Diabetes Care, 2013, 36, 1297-1303.	4.3	59
64	Associations Between Arterial Elasticity and Markers of Inflammation in Healthy Older Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 382-388.	1.7	7
65	Perceived Stress Is Associated With Incident Coronary Heart Disease and Allâ€™Cause Mortality in Lowâ€™ but Not Highâ€™Income Participants in the Reasons for Geographic And Racial Differences in Stroke Study. Journal of the American Heart Association, 2013, 2, e000447.	1.6	99
66	Longitudinal Determinants of Left Ventricular Mass and Geometry. Circulation: Cardiovascular Imaging, 2013, 6, 769-775.	1.3	90
67	Effects of Antihypertensive Drugs on Arterial Stiffness. Cardiology in Review, 2012, 20, 259-263.	0.6	119
68	Blood Pressure Indexes and End-Stage Renal Disease Risk in Adults With Chronic Kidney Disease. American Journal of Hypertension, 2012, 25, 789-796.	1.0	37
69	Association of Race and Sex With Risk of Incident Acute Coronary Heart Disease Events. JAMA - Journal of the American Medical Association, 2012, 308, 1768.	3.8	263
70	Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. Journal of the American Society of Hypertension, 2012, 6, 66-72.	2.3	24
71	Subclinical, hemodynamic, and echocardiographic abnormalities of high pulse pressure in hypertensive and non-hypertensive adults. American Journal of Cardiovascular Disease, 2012, 2, 309-17.	0.5	5
72	Abstract 2593: Pulse and Mean Arterial Pressure as Predictors of Stroke in the REGARDS Study. Stroke, 2012, 43, .	1.0	2

#	ARTICLE	IF	CITATIONS
73	The Global Burden of Cardiovascular Disease: The Role of Endothelial Function and Arterial Elasticity in Cardiovascular Disease as Novel and Emerging Biomarkers. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 187-195.	0.8	6
74	Lipoprotein Lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the MetS. <i>Lipids in Health and Disease</i> , 2011, 10, 143.	1.2	9
75	High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional study. <i>Lipids in Health and Disease</i> , 2011, 10, 181.	1.2	74
76	A clustering analysis of lipoprotein diameters in the metabolic syndrome. <i>Lipids in Health and Disease</i> , 2011, 10, 237.	1.2	18
77	Myocardial Infarction After Carotid Stenting and Endarterectomy. <i>Circulation</i> , 2011, 123, 2571-2578.	1.6	174
78	Is Randomization to Placebo Safe? Risk in Placebo-Controlled Angina Trials: Angina Risk Meta-Analysis. <i>Cardiology</i> , 2011, 120, 174-181.	0.6	4
79	Prehypertension, Racial Prevalence and Its Association With Risk Factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Hypertension</i> , 2011, 24, 194-199.	1.0	50
80	The Association of Statin Use and Statin Type and Cognitive Performance: Analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Clinical Cardiology</i> , 2010, 33, 280-288.	0.7	44
81	Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1153-1158.	4.3	98
82	Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study. <i>SRX Pharmacology</i> , 2010, 2010, 1-8.	0.2	3
83	Trust in physicians and blood pressure control in blacks and whites being treated for hypertension in the REGARDS study. <i>Ethnicity and Disease</i> , 2010, 20, 282-9.	1.0	14
84	Does Prehypertension Represent an Increased Risk for Incident Hypertension and Adverse Cardiovascular Outcome?. <i>Hypertension</i> , 2009, 54, 954-955.	1.3	3
85	TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 16.	1.2	12
86	Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 485-491.	0.9	11
87	Smoking, inflammatory patterns and postprandial hypertriglyceridemia. <i>Atherosclerosis</i> , 2009, 203, 633-639.	0.4	33
88	Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?. <i>Preventive Medicine</i> , 2008, 47, 161-166.	1.6	22
89	Analysis of US Food and Drug Administration Warning Letters. <i>Pharmaceutical Medicine</i> , 2008, 22, 119-125.	1.0	10
90	Vascular Stiffness and the "Chicken-or-the-Egg" Question. <i>Hypertension</i> , 2008, 51, 177-178.	1.3	8

#	ARTICLE	IF	CITATIONS
91	Endothelial Function in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2008, 30, 20-25.	0.3	58
92	Postmarketing Research. , 2008, , 73-91.		0
93	Health Knowledge About Symptoms of Heart Attack and Stroke in Adult Survivors of Childhood Acute Lymphoblastic Leukemia. Annals of Epidemiology, 2007, 17, 778-781.	0.9	3
94	Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-reporting Systems. Journal of Clinical Pharmacology, 2007, 47, 1074-1086.	1.0	58
95	Clinical Trial Design Issues: At Least 10 Things You Should Look For in Clinical Trials. Journal of Clinical Pharmacology, 2006, 46, 1106-1115.	1.0	26
96	Antihypertensive safety and efficacy and physician and patient satisfaction: results from a phase 4 practice-based clinical experience trial with diltiazem LA. Advances in Therapy, 2006, 23, 284-294.	1.3	6
97	Pharmacogenetics of antihypertensive treatment. Vascular Pharmacology, 2006, 44, 107-118.	1.0	78
98	Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer, 2006, 107, 1303-1312.	2.0	242
99	Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Expert Opinion on Pharmacotherapy, 2005, 6, 765-776.	0.9	17
100	Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. American Heart Journal, 2005, 149, e1-e9.	1.2	15
101	Determinants of radial artery pulse wave analysis in asymptomatic individuals. American Journal of Hypertension, 2004, 17, 647-653.	1.0	96
102	Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. American Journal of Hypertension, 2003, 16, 51-58.	1.0	44
103	Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. American Journal of Hypertension, 2003, 16, 265-269.	1.0	173
104	Diltiazem hydrochloride: New technologies and evolution of diltiazem. Clinical Cardiology, 2003, 26, 16-24.	0.7	1
105	Arterial compliance abnormalities in isolated systolic hypertension. American Journal of Hypertension, 2001, 14, 1007-1011.	1.0	64
106	Hypertension syndrome and cardiovascular events. Postgraduate Medicine, 2001, 110, 29-36.	0.9	14
107	Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia. Clinical Cardiology, 2000, 23, 524-529.	0.7	1
108	Angiotensin converting enzyme inhibitors: Are they preferred first-line therapy?. Current Hypertension Reports, 2000, 2, 392-397.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Age-Related Abnormalities in Arterial Compliance Identified by Pressure Pulse Contour Analysis. Hypertension, 1999, 33, 1392-1398.	1.3	324
110	Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. American Journal of Cardiology, 1999, 83, 507-514.	0.7	73
111	Prospects for therapy of nitrate tolerance. Lancet, The, 1999, 353, 1545-1546.	6.3	25
112	Additional antianginal and antiischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris. Clinical Cardiology, 1998, 21, 483-490.	0.7	5
113	Clinical Mechanisms of Nitrate Action. American Journal of Cardiology, 1998, 81, 49A-53A.	0.7	9
114	Hypertension, hypertrophy, hormones, and the heart. American Heart Journal, 1998, 135, S16-S20.	1.2	12
115	The Importance of Arterial Compliance in Cardiovascular Drug Therapy. Journal of Clinical Pharmacology, 1998, 38, 202-212.	1.0	30
116	The Relevance of L-Type Calcium Antagonists: A Profile of Mibefradil. Journal of Clinical Pharmacology, 1998, 38, 659-669.	1.0	19
117	Safety and Efficacy of Monotherapy with Fantofarone, a Novel Calcium Channel Antagonist, in Patients with Chronic Stable Angina Pectoris. Journal of Clinical Pharmacology, 1997, 37, 53-57.	1.0	7
118	Vascular Compliance and Cardiovascular Disease A Risk Factor or a Marker?. American Journal of Hypertension, 1997, 10, 1175-1189.	1.0	245
119	The Time Course of Left Ventricular Remodeling After Acute Myocardial Infarction. American Journal of Cardiology, 1997, 80, 506-507.	0.7	7
120	Effect of Extended-Release Isosorbide Mononitrate One Hour After Dosing in Patients With Stable Angina Pectoris This study was supported by a grant from the Schering Corporation, Kenilworth, New Jersey.. American Journal of Cardiology, 1997, 80, 1546-1550.	0.7	7
121	Atherosclerosis: Risk factors and the vascular endothelium. American Heart Journal, 1996, 131, 379-384.	1.2	162
122	The placebo effect in cardiovascular disease. American Heart Journal, 1996, 132, 1207-1221.	1.2	86
123	The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl. American Journal of Cardiology, 1996, 77, 83-85.	0.7	23
124	Antianginal and Antiischemic Efficacy of Monotherapy Extended-Release Nisoldipine (Coat Core) in Chronic Stable Angina. Journal of Clinical Pharmacology, 1995, 35, 780-784.	1.0	10
125	Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. American Journal of Cardiology, 1995, 75, E68-E70.	0.7	9
126	The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Clinical Therapeutics, 1995, 17, 12-29.	1.1	14



#	ARTICLE	IF	CITATIONS
127	723-1 Selective Reduction of Heart Rate with the Sinus Node Inhibitor Zatebradine (ULFS 49) Does not Lead to the Expected Improvements in Exercise Duration in Patients with Angina Pectoris. <i>Journal of the American College of Cardiology</i> , 1995, 25, 127A.	1.2	6
128	Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris. <i>American Journal of Cardiology</i> , 1994, 73, 1165-1168.	0.7	3
129	Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. <i>American Journal of Cardiology</i> , 1994, 73, 213-218.	0.7	4
130	Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. <i>American Journal of Cardiology</i> , 1994, 74, 9-17.	0.7	22
131	Phenomenon of nitrate tolerance. <i>American Heart Journal</i> , 1994, 128, 137-146.	1.2	73
132	Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. <i>American Journal of Cardiology</i> , 1993, 72, 1249-1256.	0.7	108
133	Is the site of maximal coronary artery narrowing the culprit for future myocardial infarction?. <i>American Journal of Cardiology</i> , 1993, 72, 861-862.	0.7	2
134	Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1605-1611.	1.2	24
135	Amlodipine combined with beta blockade for chronic angina: Results of a multicenter, placebo-controlled, randomized double-blind study. <i>Clinical Cardiology</i> , 1992, 15, 519-524.	0.7	26
136	Update on Nitrate Therapy. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 697-701.	1.0	5
137	Clinical aspects of silent myocardial ischemia in China. <i>American Journal of Cardiology</i> , 1991, 67, 1146-1147.	0.7	0
138	Exposing Patients With Chronic, Stable, Exertional Angina to Placebo Periods in Drug Trials. <i>JAMA - Journal of the American Medical Association</i> , 1991, 265, 1550.	3.8	30
139	Long-Term Therapy with Benazepril in Patients with Congestive Heart Failure: Effects on Clinical Status and Exercise Tolerance. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 1106-1111.	1.0	10
140	Safety and Efficacy of Amlodipine Added to Hydrochlorothiazide Therapy in Essential Hypertension. <i>American Journal of Hypertension</i> , 1989, 2, 154-157.	1.0	33
141	Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: Results of a multicenter comparison of dilevalol and metoprolol. <i>American Journal of Cardiology</i> , 1989, 63, 158-163.	0.7	17
142	Effects of dilevalol, metoprolol and atenolol on left ventricular mass and function in nonelderly and elderly hypertensive patients. <i>American Journal of Cardiology</i> , 1989, 63, 169-174.	0.7	9
143	Clinical safety and efficacy of once-daily amlodipine for chronic stable angina pectoris. <i>American Heart Journal</i> , 1989, 118, 1127-1128.	1.2	8
144	Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. <i>Journal of the American College of Cardiology</i> , 1989, 13, 786-793.	1.2	200

#	ARTICLE	IF	CITATIONS
145	The Efficacy and Safety of Dilevalol in Patients with Chronic Stable Angina Pectoris. Journal of Clinical Pharmacology, 1989, 29, 983-988.	1.0	1
146	Regression of Left Ventricular Hypertrophy in Treated Hypertensive Patients with Dilevalol and Metoprolol. A Double Blind Randomized Study. Journal of Clinical Pharmacology, 1989, 29, 791-797.	1.0	6
147	The Impact of Antianginal Drug Therapy on Asymptomatic Myocardial Ischemia. Journal of Clinical Pharmacology, 1989, 29, 722-727.	1.0	3
148	Silent Myocardial Ischemia. Southern Medical Journal, 1989, 82, 32-34.	0.3	2
149	Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. American Journal of Cardiology, 1988, 62, 518-522.	0.7	26
150	Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction. American Journal of Cardiology, 1988, 61, 21-25.	0.7	21
151	Relation of results of exercise stress tests in young women to phases of the menstrual cycle. American Journal of Cardiology, 1988, 61, 197-199.	0.7	42
152	A Paradoxical Response to Arrhythmia Therapy. Hospital Practice (1995), 1987, 22, 225-226.	0.5	0
153	The Role of Exercise Testing in the Identification of Patients with Silent Myocardial ischemia. Cardiology Clinics, 1986, 4, 705-715.	0.9	4
154	Management of Cardiac Arrhythmias. Hospital Practice (1995), 1985, 20, 127-148.	0.5	0
155	Predischarge Post-Myocardial Infarction Testing: Exercise Electrocardiography. Cardiology Clinics, 1984, 2, 379-390.	0.9	0
156	Comparison of the antiarrhythmic effects of acebutolol and propranolol in the treatment of ventricular arrhythmias. American Journal of Cardiology, 1983, 52, 992-995.	0.7	8
157	The Rhythms of Aging. Chest, 1982, 81, 266-267.	0.4	4
158	Chloral Hydrate Overdose and Cardiac Arrhythmias. Chest, 1980, 77, 232-235.	0.4	37
159	Arrhythmias Detected by Ambulatory Monitoring. Chest, 1980, 77, 722-725.	0.4	116
160	Echocardiographic incidence of pericardial effusion in patients resuscitated by emergency medical technicians. Jacep, 1979, 8, 6-8.	0.3	9
161	Atrial fibrillatory wave size and etiology of heart disease. American Heart Journal, 1979, 98, 274.	1.2	0
162	Occurrence of Frequent Complex Arrhythmias Detected by Ambulatory Monitoring. Chest, 1979, 75, 565-568.	0.4	131

#	ARTICLE	IF	CITATIONS
163	When Cardiac Patients Become Surgical Patients. Hospital Practice (1995), 1979, 14, 165-173.	0.5	6
164	Traumatic Coronary Artery Fistula. Southern Medical Journal, 1978, 71, 649-651.	0.3	5
165	The problems of patients with cardiovascular disease undergoing dental treatment. Journal of the American Dental Association, 1977, 94, 1158-1162.	0.7	7
166	Left atrial size in patients with atrial fibrillation: an echocardiographic study. American Journal of the Medical Sciences, 1976, 272, 57-64.	0.4	12